surmount-1 tirzepatide weight loss nondiabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Tirzepatide weight loss timeline: what

Add-on to metformin with or without SGLT2 inhibitor SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1444 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin degludec 100 units/mL once daily

absolute and percent change in body weight at week 72

Tirzepatide is a once-weekly, dual-incretin peptide it activates both the GIP and the GLP-1 receptor from a single molecule and in published obesity trials it has produced some of the largest average weight reductions of any incretin agent studied to date

Step 3: Prescription and delivery Once approved, your prescription goes to the compounding pharmacy

Important Safety Information